BR0211151A - Composição vacinal e método de fabricação da mesma - Google Patents

Composição vacinal e método de fabricação da mesma

Info

Publication number
BR0211151A
BR0211151A BR0211151-9A BRPI0211151A BR0211151A BR 0211151 A BR0211151 A BR 0211151A BR PI0211151 A BRPI0211151 A BR PI0211151A BR 0211151 A BR0211151 A BR 0211151A
Authority
BR
Brazil
Prior art keywords
valence
vaccine composition
aluminum hydroxide
adsorbed
vaccine
Prior art date
Application number
BR0211151-9A
Other languages
English (en)
Inventor
Alain Francon
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8866367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0211151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of BR0211151A publication Critical patent/BR0211151A/pt
Publication of BRPI0211151B1 publication Critical patent/BRPI0211151B1/pt
Publication of BRPI0211151B8 publication Critical patent/BRPI0211151B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO VACINAL E MéTODO DE FABRICAçãO DA MESMA". A invenção tem por objeto uma composição vacinal, que compreende pelo menos duas valências: (I) uma primeira valência que é adjuvantada com o hidróxido de alumínio e (II) uma segunda valência que contém um poli-sacarídeo de cápsula bacteriana que comporta um ou grupamentos O-acetis e que não é adsorvida sobre o hidróxido alumínio, em virtude da presença de um composto protetor que pode ser um fosfato, um citrato ou ainda um carbonato e que impede essa adsorção. A primeira valência pode ser qualquer valência vacinal. Segundo um modo particular, a composição vacinal compreende (I) a valência Hepatite A, adsorvida sobre hidróxido de alumínio e (II) a valência febre tifóide constituída por poli-sacarídeo Vi da cápsula de Salmonella typhi.
BR0211151-9 2001-08-08 2002-07-31 composição vacinal e método de fabricação da mesma BRPI0211151B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/10573 2001-08-08
FR0110573A FR2828406B1 (fr) 2001-08-08 2001-08-08 Composition vaccinale bivalente havi
PCT/FR2002/002770 WO2003013600A1 (fr) 2001-08-08 2002-07-31 Composition vaccinale comprenant au moins deux valances, l'une adjuvantee, l'autre pas

Publications (3)

Publication Number Publication Date
BR0211151A true BR0211151A (pt) 2004-08-10
BRPI0211151B1 BRPI0211151B1 (pt) 2019-07-09
BRPI0211151B8 BRPI0211151B8 (pt) 2021-05-25

Family

ID=8866367

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211151-9 BRPI0211151B8 (pt) 2001-08-08 2002-07-31 composição vacinal e método de fabricação da mesma

Country Status (22)

Country Link
US (1) US7404960B2 (pt)
EP (1) EP1416958B2 (pt)
JP (1) JP4221291B2 (pt)
KR (1) KR100881703B1 (pt)
CN (1) CN1282486C (pt)
AT (1) ATE357929T1 (pt)
AU (1) AU2002342949B2 (pt)
BR (1) BRPI0211151B8 (pt)
CA (1) CA2455406C (pt)
CY (1) CY1107619T1 (pt)
DE (1) DE60219177T3 (pt)
DK (1) DK1416958T4 (pt)
ES (1) ES2284940T5 (pt)
FR (1) FR2828406B1 (pt)
HU (1) HU228216B1 (pt)
IL (2) IL159519A0 (pt)
MX (1) MXPA04001125A (pt)
NZ (1) NZ530727A (pt)
PL (1) PL215134B1 (pt)
PT (1) PT1416958E (pt)
WO (1) WO2003013600A1 (pt)
ZA (1) ZA200400022B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738682A1 (en) 2004-04-15 2005-10-15 Eng-Hong Lee Soft gel delivery system for treating poultry
MX2009002560A (es) * 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
KR101101901B1 (ko) * 2009-01-30 2012-01-02 주식회사 리노 주방용 선반
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
CN102526724B (zh) * 2011-01-14 2015-07-22 四川大学 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
FR2985663B1 (fr) 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1107787B1 (en) * 1998-08-28 2003-05-14 GlaxoSmithKline Biologicals S.A. Salmonella typhi vaccine compositions
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions

Also Published As

Publication number Publication date
HUP0401182A2 (hu) 2004-09-28
DE60219177T2 (de) 2008-01-24
WO2003013600A1 (fr) 2003-02-20
ATE357929T1 (de) 2007-04-15
BRPI0211151B1 (pt) 2019-07-09
JP2005501081A (ja) 2005-01-13
DK1416958T4 (da) 2012-07-09
FR2828406B1 (fr) 2005-06-24
IL159519A (en) 2010-11-30
ES2284940T5 (es) 2012-07-02
JP4221291B2 (ja) 2009-02-12
PL215134B1 (pl) 2013-10-31
DK1416958T3 (da) 2007-07-30
US20040170648A1 (en) 2004-09-02
FR2828406A1 (fr) 2003-02-14
EP1416958B2 (fr) 2012-03-14
KR20040043182A (ko) 2004-05-22
HUP0401182A3 (en) 2004-10-28
CN1541108A (zh) 2004-10-27
EP1416958B1 (fr) 2007-03-28
HU228216B1 (en) 2013-02-28
BRPI0211151B8 (pt) 2021-05-25
CA2455406A1 (en) 2003-02-20
AU2002342949B2 (en) 2007-07-05
PL367904A1 (en) 2005-03-07
NZ530727A (en) 2004-06-25
MXPA04001125A (es) 2004-05-20
CY1107619T1 (el) 2013-04-18
KR100881703B1 (ko) 2009-02-06
CA2455406C (en) 2012-03-13
DE60219177T3 (de) 2012-08-30
ES2284940T3 (es) 2007-11-16
ZA200400022B (en) 2006-05-31
IL159519A0 (en) 2004-06-01
US7404960B2 (en) 2008-07-29
EP1416958A1 (fr) 2004-05-12
CN1282486C (zh) 2006-11-01
DE60219177D1 (de) 2007-05-10
PT1416958E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
PT1401489E (pt) Solubilizacao de polissacaridos capsulares
AU2001276721A1 (en) Salts of benzimidazole compound and use thereof
DE3874796D1 (de) Brandgeschuetzte polyamidmischung mit guter hitzeresistenter eigenschaft.
BR0211151A (pt) Composição vacinal e método de fabricação da mesma
SE0102315D0 (sv) Compounds
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
Francois et al. Recurrent septic shock due to Streptococcus suis
FI870616A (fi) Valon vaikutuksesta hajoavina ja lämpöstabiloituina kalvoina käytettäviä polymeerikoostumuksia
ES2194279T3 (es) Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina.
BR0210991A (pt) Polissacarìdeo substituìdo, método para depositar um silicone sobre um substrato, composição, e, uso da composição
BR0101691A (pt) Composições de pelìcula de poliolefina compropriedades de antiembaçamento permanentes
BR9910917A (pt) Inserto moldado com calor
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
GR3019197T3 (en) Derivatives of hexahydroazepines, procedure for their preparation and pharmaceutical compositions containing same
ES2087948T3 (es) Composicion de resina altamente antioxidante.
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
BR0008914A (pt) Método para a diagnose e tratamento do carcinoma, sua preparação e uso da hipericina
BR9815953A (pt) Vacinas contra infecção provocada por escherichia coli o157
Mervat E et al. Effect of different types of finshing lines and etching methods of the enamel and dentin on the marginal integrity of Hi-ceram cowns
KR870002847A (ko) 인간 피브리노겐 제제의 가열 처리방법
BR9910465A (pt) Uso de um agente que mantém ou melhora a barreira de permeabilidade da gengiva
BR0107479A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento e/ou profilaxia de doenças
KR920019354A (ko) 9-아미노-1,2,3,4- 테트라하이드로아크리딘-1-올 및 관련 화합물의 aids치료용 용도
Haman Ahmed Habib Antimicrobial susceptibility of helicobacter pylori isolated from dyspeptic patients in a teaching hospital in Riyadh, Saudi Arabia
MXPA97008744A (es) Proceso para la obtencion de derivados del 1',3',3'-trimetilespiro[2h-1]benzopirano-oxobencil-2,'-indolina para su aplicacion como compuestos fotocromaticos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 31/07/2022